Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

by Business Wire • 2025/05/29 • 0 Comments

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in New York, New York. Dr. Brady’s conversation with Clara Dong is scheduled to begin at 4:20 p

← iVeena Announces IND Submission to the U.S. FDA for a Phase 2 Clinical Trial for Pediatric Myopia

Drug Device Combination Products Market Report 2025: Injectable, Transdermal Patch, Infusion Pump, Drug-eluting Stent, Inhaler Forecasts to 2030 – ResearchAndMarkets.com →

Post navigation